Pharvaris Closes $201.2 Million Public Offering
Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company, recently announced a significant financial milestone. The company has closed an upsized underwritten public offering involving 9,562,500 ordinary shares. This offering also included the full exercise of the underwriters’ option to purchase an additional 1,312,500 ordinary shares, along with pre-funded warrants to acquire 500,000 additional ordinary shares. The total gross proceeds from this offering reached approximately $201.2 million, before subtracting any underwriting discounts or expenses. Remarkably, all shares offered were sold directly by Pharvaris.
Strategic Management Team at the Helm
This successful offering was backed by a robust team of financial advisors. Morgan Stanley, along with Leerink Partners, Cantor, Oppenheimer & Co., and Van Lanschot Kempen, served as joint book-running managers. Their expertise was pivotal in achieving this impressive capital raise, which will bolster Pharvaris's capacity to advance its pioneering therapeutic developments.
Securities Registration and Compliance
The shares that were offered in this public offering are part of an effective shelf registration statement that Pharvaris had previously filed with the U.S. Securities and Exchange Commission (SEC). It's important to note that this offering was conducted solely through existing documentation, including a prospectus and a prospectus supplement, included in the registration statement.
Accessibility of Offering Documentation
For those interested in the offering, copies of the final prospectus supplement are accessible. Investors and other interested parties can request these documents from the involved banks, including Morgan Stanley and Leerink Partners, at their respective New York and Boston offices. These documents play a crucial role for potential investors to understand the terms of the offering and the implications of investing in Pharvaris.
Pharvaris's Vision and Goals
Pharvaris is on a mission to develop innovative oral bradykinin B2 receptor antagonists aimed at addressing the pressing needs of individuals suffering from bradykinin-mediated diseases like hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). The company seeks to offer treatment options with injectable-like efficacy and the tolerability of oral medications, allowing patients to manage their conditions proactively.
Pivotal Studies Underway
Currently, Pharvaris is evaluating the effectiveness of its lead compound, deucrictibant, in pivotal Phase 3 studies. These studies are focused both on preventing HAE attacks and providing on-demand treatment for such attacks. The ongoing research reflects Pharvaris’s commitment to driving advancements in therapeutic options, aiming to fill the gaps that many patients currently face.
Commitment to Growth and Innovation
As Pharvaris moves forward, the company plans to utilize the funds raised from this public offering to further its research and development efforts. In doing so, Pharvaris aims to enhance its portfolio of treatments, ultimately striving to improve the quality of life for patients coping with debilitating conditions like HAE.
Frequently Asked Questions
What was the total amount raised in Pharvaris's public offering?
Pharvaris raised approximately $201.2 million in its recent public offering.
Which companies acted as book-running managers for the offering?
Morgan Stanley, Leerink Partners, Cantor, Oppenheimer & Co., and Van Lanschot Kempen were the joint book-running managers.
What indications is Pharvaris focusing on with its therapies?
Pharvaris is focusing on the treatment of hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).
What is the lead compound being evaluated in Pharvaris's studies?
The lead compound being evaluated is deucrictibant, currently in pivotal Phase 3 studies.
How will Pharvaris use the funds from the public offering?
Pharvaris intends to utilize the funds to further research and development of its therapeutic portfolio.
